MaxCyte (NASDAQ:MXCT) Issues Earnings Results, Beats Estimates By $0.03 EPS

MaxCyte (NASDAQ:MXCT) posted its quarterly earnings results on Tuesday. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.03, Zacks reports. The company had revenue of $8.16 million during the quarter, compared to analysts’ expectations of $7.39 million. MaxCyte had a negative net margin of 81.40% and a negative return on equity of 14.71%.

Here are the key takeaways from MaxCyte’s conference call:

• Positive Sentiment: MaxCyte agreed to acquire Akron Bio for $151.8 million in cash, stock, and deferred payments. Akron is expected to contribute $28 million in 2026 revenue and $7 million–$8 million in EBITDA; management projects combined 2027 cash burn below $10 million, while the deal will be funded largely with cash and new borrowings.
• Positive Sentiment: Third-quarter revenue rose 49% year over year to $10.2 million, including 27% growth in core revenue. MaxCyte raised its 2026 standalone revenue outlook to at least $34.5 million, citing stronger core performance and SPL milestones and royalties; some instrument purchases arrived earlier than expected.
• Positive Sentiment: Akron would broaden MaxCyte’s exposure across cell therapy manufacturing and more than double its addressable program base, with limited current customer overlap offering cross-selling potential. Management expects the combined company to have more than $60 million in 2026 revenue and identified $3 million–$4 million in potential cost efficiencies.
• Positive Sentiment: MaxCyte reported $2 million in SPL revenue, including $1 million of Casgevy royalties, and said royalty revenue is beginning to become a more meaningful contributor. Vertex reported Casgevy sales of about $99 million in Q3, up roughly 30% sequentially, while MaxCyte said it supports multiple pivotal trials and could have up to three approved products within 24 months.

MaxCyte Price Performance

Shares of NASDAQ MXCT traded down $0.01 during mid-day trading on Thursday, hitting $1.09. 515,458 shares of the stock traded hands, compared to its average volume of 1,071,615. The company has a market cap of $113.01 million, a PE ratio of -4.17 and a beta of 1.49. MaxCyte has a twelve month low of $0.64 and a twelve month high of $1.80. The firm has a 50 day simple moving average of $1.26 and a two-hundred day simple moving average of $1.07.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on MXCT. Weiss Ratings cut shares of MaxCyte from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, November 4th. BTIG Research reaffirmed a “neutral” rating on shares of MaxCyte in a research report on Monday, August 24th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $5.00.

MaxCyte Company Profile

MaxCyte, Inc. (NASDAQ: MXCT) is a life sciences company that develops technologies for engineering cells used in biopharmaceutical research and the development of cell-based therapies. Its platform is designed to help researchers modify cells efficiently for applications including cell therapy, gene editing, immuno-oncology and other advanced biological treatments. The company’s primary offering is the ExPERT platform, which combines Flow Electroporation technology with specialized instruments, single-use processing assemblies, software and related support services.